


REMARKS

Currently claims 1 – 8 and 10 - 12 are pending. Claims 3, 4, 5, 7 and 8 have been amended so as not to contain multiple dependencies. Claim 9 has been cancelled and rewritten as Claim 13 because so-called "use" claims are not by law permitted. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,


 Bonnie L. Deppenbrock
 Attorney for Applicants
 Registration No. 28,209


Date: 11/6/01
 GlaxoSmithKline
 Corporate Intellectual Property
 Five Moore Drive, P.O. Box 13398
 Research Triangle Park, NC 27709
 Phone: 919-483-1577
 Facsimile: 919-483-7988

Marked-Up Copy of Pending Claims




1. Enantiomerically enriched 3-{3-[1-(Isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]-ureido} benzoic acid, or a pharmaceutically acceptable salt or solvate thereof.
2. The enantiomerically enriched compound of Claim 1 wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 90% of said compound.
3. The enantiomerically enriched compound of Claim [1 or claim] 2, wherein the (+) enantiomer, or a pharmaceutically acceptable salt or solvate thereof, is at least 99% of said compound.
4. A pharmaceutical composition comprising the enantiomerically enriched compound as claimed in [any of claims 1 to 3] claim 1 in admixture with one or more pharmaceutically acceptable carriers and or excipients.
5. A method for treating a CCK-A mediated disease or condition comprising administration of an effective amount of compound as claimed in [any of claim 1 to 3] claim 1.
6. A method for treating a CCK-A mediated disease or condition comprising administration of the pharmaceutical composition as claimed in Claim 4.
7. The method as claimed in claim 5 [or claim 6], wherein said disease or condition is obesity, gallbladder stasis, or diabetes.
8. The method as claimed in claim 5 [or claim 6], wherein said disease or condition is obesity.
9. [The use of a compound as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of a CCK-A mediated disease or condition.]

10. A process for the preparation of a compound as claimed in claim 1 which comprises:

- (c) resolution of racemic 3-[3-[1-(isopropyl-phenyl-carbamoylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-yl]benzoic acid by chiral hplc;
- (d) reaction of the appropriate enantiomer of the amine of formula (II)




with the isocyanate of formula (III), imidazolidine of formula (IV) or optionally substituted phenyl carbamate of formula (V)



followed by removal of the carboxy protecting group R.



11. A process as claimed in claim 10 wherein the required compound of claim 1 is prepared via the racemic amine (II) which has been prepared by concomitant reduction and hydrogenolysis of the oxime (VI),



(VI)

wherein R₂ is an optionally substituted benzyl group.

12. A process as claimed in claim 11 wherein the oxime (VI) is prepared from the ortho phenylene diamine (VII) and an activated derivative of the diacid (VIII),



wherein, R_2 is an optionally substituted benzyl group.

13. A medicament for the treatment of a CCK-A mediated disease or condition comprising the compound of Claim 1.